Ketorolac: Difference between revisions

(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template))
(Switch SMW query from broadtable to table format for better layout with TOC)
 
(One intermediate revision by the same user not shown)
Line 54: Line 54:
  |?Has Route=Route
  |?Has Route=Route
  |?Has Population=Population
  |?Has Population=Population
  |format=broadtable
  |format=table
  |headers=plain
  |headers=plain
  |link=subject
  |mainlabel=-
  |sort=Has Indication
  |sort=Has Indication
  |limit=50
  |limit=50

Latest revision as of 21:56, 20 March 2026

General

  • Type: NSAID
  • Dosage Forms: 15mg/mL, 30mg/mL injection
  • Common Trade Names: Toradol

Although standard packaging provides 30mg doses current research demonstrates that the analgesic ceiling for ketorolac appears to be 10 mg if given intravenously[1]

Adult Dosing

  • Acute pain:
    • IM: 15mg x 1 or 15mg q6h
    • IV: 15mg x 1, then 15mg q6h
    • Black box warning against treatment for > 5 days

Pediatric Dosing

  • N/A

Special Populations

  • Pregnancy Rating: C
  • Lactation: Enters breast milk, use caution
  • Elderly (> 65 yo): Decrease dose by 50%
  • Renal Dosing
    • Mild-Moderate impairment: Decrease dose by 50%
    • Severe impairment or HD: Contraindicated
  • Hepatic Dosing: No dose change, but may increase LFTs

Contraindications

  • Allergy to class/drug
  • Active or prior PUD, recent GI bleed
  • Severe renal disease or HD
  • Bleeding diathesis

Adverse Reactions

Serious

  • Bleeding, MI, CVA, GI bleed/perforation, Hyperkalemia

Common

  • Dyspepsia, nausea, headache

Pharmacology

  • Onset: 20-30 minutes
  • Peak: 2-3 hours
  • Duration: 4-6 hours
  • Half-life: 2-6 hours, up to 19 hours in renal disease
  • Metabolism: Hepatic
  • Excretion: Renal
  • Mechanism of Action: NSAID, Reversible COX-1/2 inhibitor


Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
Acute pain management15-30 mg IV q6h or 30-60 mg IMNon-opioid analgesic (NSAID, parenteral)IV/IMAdult
Corneal abrasion1 drop 0.4% q6hr x 2-3 daysOphthalmic NSAID for painTopical ophthalmicAdult
Headache15-30 mg IV (30-60 mg IM)NSAID for headacheIV/IMAdult
Migraine headache15-30 mg IVNSAID adjunctIVAdult
Migraine headache15-30 mg IV (30-60 mg IM)NSAID for headacheIV/IMAdult
Sickle cell crisis15 mg q6hrNSAID for vaso-occlusive crisisIVAdult
Urolithiasis15mgFirst-line analgesicIVAdult

See Also

References

  1. Motov S et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med 2016. PMID: 27993418